Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lexicon Share Spike On Carcinoid Syndrome Phase III Data

This article was originally published in Scrip

Executive Summary

Lexicon Pharmaceuticals Inc. is looking forward to filing its first US NDA after announcing positive top-line Phase III data for its lead product, telotristat etiprate, in treating cancer patients with carcinoid syndrome inadequately controlled by the current standard of care. Shares in the firm shot up by 47% to $12.41 on NASDAQ the morning of Aug. 1, 2015 following the news.

You may also be interested in...



Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing

Intended mainly to provide evidence of a safety advantage compared to existing SGLT2 inhibitors, meeting the net-benefit primary endpoint in the inTandem3 trial puts sotagliflozin in good shape for approval as add-on glycemic-control therapy in type 1 diabetes.

Urovant’s Vibegron Flops In IBS Study

Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.

Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations

Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.

Topics

Related Companies

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel